Edesa Biotech, Inc. (EDSA) stock
EDSANasdaqPharmaceutical PreparationsFiscal year ends September 30
$1.96+0.07 (+3.70%)
Close on Nov 17, 2026Market cap $18.90MP/E –Yield –
Edesa Biotech r&d expenses
Research and development expenses are spending on new products and technology.
Edesa Biotech's R&D Expenses for the twelve months ending Jun 30, 2026 was $9.08M, up 256.3% year over year. For fiscal 2025 it was $3.67M, up 27.3% from the year before. Over ten years it grew 6.2% a year on average. The highest annual figure on record is $17.95M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $3.67M | +27.3% |
| FY2024 | Sep 30, 2024 | $2.88M | -39.9% |
| FY2023 | Sep 30, 2023 | $4.79M | -64.0% |
| FY2022 | Sep 30, 2022 | $13.34M | -25.7% |
| FY2021 | Sep 30, 2021 | $17.95M | +439.0% |
| FY2020 | Sep 30, 2020 | $3.33M | +59.5% |
| FY2018 | Sep 30, 2018 | $2.09M | +5.8% |
| FY2017 | Sep 30, 2017 | $1.97M | +14.1% |
| FY2016 | Sep 30, 2016 | $1.73M | -29.7% |
| FY2014 | Aug 31, 2014 | $2.46M | +21.8% |
| FY2013 | Aug 31, 2013 | $2.02M | -23.4% |
| FY2012 | Aug 31, 2012 | $2.63M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | $3.96M | +321.5% |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | $2.77M | +471.4% |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | $1.12M | +10.3% |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | $1.23M | +1079.9% |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | $939.07K | +4.7% |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | $484.31K | -58.8% |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | $1.02M | +44.8% |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | $103.87K | -89.1% |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | $897.31K | -12.5% |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | $1.18M | -19.3% |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | $704.46K | -48.1% |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | $953.40K | -46.9% |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | $1.03M | -77.4% |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | $1.46M | -52.1% |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | $1.36M | -65.6% |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | $1.79M | -56.5% |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | $4.55M | +1.9% |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | $3.04M | -61.8% |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | $3.95M | +186.4% |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | $4.13M | +257.5% |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | $4.46M | +290.3% |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | $7.98M | +1486.1% |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | $1.38M | +161.3% |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | $1.15M | +129.6% |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | $1.14M | +924.0% |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | $502.81K | +95.4% |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | $528.00K | +6.2% |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | $502.93K | +68.6% |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | $111.70K | -77.4% |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | $257.39K | -59.2% |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | $497.32K | -23.1% |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | $298.22K | -44.4% |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | $493.87K | +49.9% |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | $631.03K | +36.9% |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | $647.00K | -2.2% |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | $536.17K | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | $329.37K | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | $460.87K | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | $661.44K | – |
See a number that looks wrong?